News headlines about Baxter International (NYSE:BAX) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.7286623156269 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:
- Top Analyst Reports for Netflix, PNC Financial & Mondelez (finance.yahoo.com)
- Baxter International Inc. — Moody’s upgrades Baxter International to Baa1 from Baa2, stable outlook (finance.yahoo.com)
- Baxter International (BAX) Downgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- Baxter International Inc. (BAX) stock reveals return of -3.05% for the previous five trading days (analystrecommendation.com)
- Global Surgical Sealants Market Study 2018- 3M Company, Baxter International Inc and B. Braun Melsungen AG (businessservices24.com)
A number of equities research analysts have recently weighed in on BAX shares. Zacks Investment Research downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. JPMorgan Chase & Co. raised Baxter International from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Bank of America upgraded Baxter International from a “neutral” rating to a “buy” rating in a report on Tuesday, January 2nd. Evercore ISI started coverage on Baxter International in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $71.00 target price on the stock. Finally, Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price target on the stock in a report on Wednesday, January 3rd. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $71.07.
Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.11% and a net margin of 6.79%. The business had revenue of $2.77 billion for the quarter, compared to analysts’ expectations of $2.77 billion. During the same period in the previous year, the firm earned $0.57 EPS. The business’s quarterly revenue was up 4.9% on a year-over-year basis. equities analysts expect that Baxter International will post 2.78 earnings per share for the current year.
Baxter International declared that its Board of Directors has initiated a share buyback plan on Tuesday, February 20th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 2nd. Shareholders of record on Friday, March 2nd will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.98%. The ex-dividend date of this dividend is Thursday, March 1st. Baxter International’s payout ratio is 49.61%.
In other Baxter International news, Director Carole J. Shapazian sold 4,990 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $66.05, for a total transaction of $329,589.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total value of $1,918,947.00. The disclosure for this sale can be found here. 0.05% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Baxter International (BAX) Stock Price” was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/30/baxter-international-bax-earns-daily-news-sentiment-score-of-0-16/1974446.html.
About Baxter International
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.